Author (year) | Country | Design | Patients | Patient number | Mean age (year) | Male (%) | With asthma (%) | LTRAs | SAHs | Concurrent treatment for AR | Duration (weeks) | Outcomes |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Meltzer 2000 | The US | R, DB | SAR patients aged 15–75 y | 187 | 33.6 | 44.4 | 31.1 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 2 | DNSS, NSS, CSS, DESS, RQLQ |
Nayak 2002 | The US | R, DB | SAR patients aged 15–82 y | 456 | 36.6 | 36.7 | 20.9 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 2 | DNSS, NSS, CSS, DESS, RQLQ |
Philip 2002 | The US | R, DB | Non-smoking SAR patients aged 15–81 y | 950 | 36.3 | 65.5 | 25.7 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 2 | DNSS, NSS, CSS, DESS, RQLQ |
van Adelsberg 2003a | The US | R, DB | Non-smoking SAR patients aged 15–85 y | 693 | 36.2 | 40.1 | 23.4 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 2 | DNSS, NSS, CSS, DESS, RQLQ |
van Adelsberg 2003b | the US | R, DB | SAR patients aged 15–82 y | 628 | 36.3 | 33.2 | 22.4 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 4 | DNSS, NSS, CSS, DESS, RQLQ |
Lee 2004 | UK | R, DB, CO | Adult PAR patients | 12 | 42 | 33.3 | NR | Montelukast 10Â mg/d | Fexofenadine 180Â mg/d | None | 1 | DNSS |
Di Lorenzo 2004 | Italy | R, DB | SAR patients aged 12–50 y | 40 | 31.8 | 35 | NR | Montelukast 10 mg/d | cetirizine 10 mg/d | Fluticasone propionate aqueous nasal spray | 6 | DNSS |
Hsieh 2004 | China | R, DB | Child PAR patients aged 6–12 y | 40 | 8.1 | 62.5 | NR | Montelukast 5 mg/d | Cetirizine 10 mg/d | None | 12 | DNSS |
Ciebiada 2006-levo | Poland | R, DB, CO | Adult PAR patients aged 18–65 y | 20 | 23.7 | 30 | 0 | Montelukast 10 mg/d | Levocetirizine 5 mg/d | None | 6 | DNSS, DESS |
Ciebiada 2006-deslo | Poland | R, DB, CO | Adult PAR patients aged 18–65 y | 20 | 34.1 | 20 | 0 | Montelukast 10 mg/d | Desloratadine 5 mg/d | None | 6 | DNSS, DESS |
Jiang 2006 | China | R | PAR patients aged 15–65y | 63 | 28.6 | 41.3 | NR | Zafirlukast 40 mg /d | Loratadine 10 mg/d | None | 2 | DNSS |
Philip 2007 | the US | R, DB | PAR patients aged 15–85y | 752 | 35.5 | 33.1 | 23.7 | Montelukast 10 mg/d | Cetirizine 10 mg/d | None | 6 | DNSS, RQLQ |
Lu 2009-1 | the US | R, DB | SAR patients aged 15–85 y | 228 | 35.2 | 36.3 | 24.1 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 2 | DNSS, CSS |
Lu 2009-2 | the US | R, DB | SAR patients aged 15–85 y | 267 | 30.9 | 38.9 | 70.8 | Montelukast 10 mg/d | Loratadine 10 mg/d | None | 2 | DNSS, CSS |
Liu 2016 | China | R | SAR patients aged 16–69 y | 64 | 37.3 | 54.2 | NR | Montelukast 10 mg/d | Fexofenadine 120 mg/d | Nasal budesonide | 4 | DNSS, RQLQ |
Jia 2017 | China | R | PAR patients aged 12–56 y | 38 | 29.7 | 54.4 | 0 | Montelukast 10 mg/d | Loratadine 10 mg/d | Nasal mometasone | 4 | DNSS |